CATHETER PRECISION INC (VTAK) Stock Fundamental Analysis

NYSEARCA:VTAK • US74933X7084

1.59 USD
-0.04 (-2.45%)
Last: Feb 26, 2026, 12:59 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, VTAK scores 2 out of 10 in our fundamental rating. VTAK was compared to 185 industry peers in the Health Care Equipment & Supplies industry. VTAK has a bad profitability rating. Also its financial health evaluation is rather negative. VTAK shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • VTAK had negative earnings in the past year.
  • VTAK had a negative operating cash flow in the past year.
  • In the past 5 years VTAK always reported negative net income.
  • VTAK had a negative operating cash flow in each of the past 5 years.
VTAK Yearly Net Income VS EBIT VS OCF VS FCFVTAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • VTAK has a Return On Assets of -94.12%. This is in the lower half of the industry: VTAK underperforms 77.84% of its industry peers.
  • VTAK has a worse Return On Equity (-354.30%) than 78.38% of its industry peers.
Industry RankSector Rank
ROA -94.12%
ROE -354.3%
ROIC N/A
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
VTAK Yearly ROA, ROE, ROICVTAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • VTAK's Gross Margin of 92.33% is amongst the best of the industry. VTAK outperforms 98.38% of its industry peers.
  • The Profit Margin and Operating Margin are not available for VTAK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTAK Yearly Profit, Operating, Gross MarginsVTAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • VTAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, VTAK has more shares outstanding
  • VTAK has a worse debt/assets ratio than last year.
VTAK Yearly Shares OutstandingVTAK Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K
VTAK Yearly Total Debt VS Total AssetsVTAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • VTAK has an Altman-Z score of -18.10. This is a bad value and indicates that VTAK is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of VTAK (-18.10) is worse than 88.11% of its industry peers.
  • VTAK has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • VTAK has a Debt to Equity ratio of 0.00. This is in the better half of the industry: VTAK outperforms 73.51% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.1
ROIC/WACCN/A
WACC9.21%
VTAK Yearly LT Debt VS Equity VS FCFVTAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M -30M

2.3 Liquidity

  • VTAK has a Current Ratio of 0.44. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • VTAK has a Current ratio of 0.44. This is amonst the worse of the industry: VTAK underperforms 92.97% of its industry peers.
  • A Quick Ratio of 0.43 indicates that VTAK may have some problems paying its short term obligations.
  • VTAK's Quick ratio of 0.43 is on the low side compared to the rest of the industry. VTAK is outperformed by 92.43% of its industry peers.
Industry RankSector Rank
Current Ratio 0.44
Quick Ratio 0.43
VTAK Yearly Current Assets VS Current LiabilitesVTAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • VTAK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.00%, which is quite impressive.
  • Looking at the last year, VTAK shows a very strong growth in Revenue. The Revenue has grown by 37.61%.
  • Measured over the past years, VTAK shows a very strong growth in Revenue. The Revenue has been growing by 167.26% on average per year.
EPS 1Y (TTM)70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.12%
Revenue 1Y (TTM)37.61%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%127.96%

3.2 Future

  • Based on estimates for the next years, VTAK will show a very strong growth in Earnings Per Share. The EPS will grow by 40.75% on average per year.
  • Based on estimates for the next years, VTAK will show a very strong growth in Revenue. The Revenue will grow by 312.31% on average per year.
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VTAK Yearly Revenue VS EstimatesVTAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
VTAK Yearly EPS VS EstimatesVTAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2023 2024 2025 2026 -200K -400K -600K -800K -1M

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VTAK. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTAK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTAK Price Earnings VS Forward Price EarningsVTAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTAK Per share dataVTAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

  • A more expensive valuation may be justified as VTAK's earnings are expected to grow with 40.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.75%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for VTAK!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CATHETER PRECISION INC

NYSEARCA:VTAK (2/26/2026, 12:59:05 PM)

1.59

-0.04 (-2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13
Earnings (Next)03-19
Inst Owners0.03%
Inst Owner Change295952%
Ins Owners1.47%
Ins Owner Change4.3%
Market Cap2.66M
Revenue(TTM)600.00K
Net Income(TTM)-24.06M
Analysts85.71
Price Target38.76 (2337.74%)
Short Float %1.24%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-59.17%
Min Revenue beat(2)-65.07%
Max Revenue beat(2)-53.27%
Revenue beat(4)0
Avg Revenue beat(4)-65.2%
Min Revenue beat(4)-91.15%
Max Revenue beat(4)-51.31%
Revenue beat(8)0
Avg Revenue beat(8)-68.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.43
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-73.84
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-6.14
FCFYN/A
OCF(TTM)-6.13
OCFYN/A
SpS0.36
BVpS4.07
TBVpS-9.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -94.12%
ROE -354.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.33%
FCFM N/A
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.08%
Cap/Sales 3.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.44
Quick Ratio 0.43
Altman-Z -18.1
F-Score5
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)3.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)51.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.12%
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)37.61%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%127.96%
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.89%
OCF growth 3YN/A
OCF growth 5YN/A

CATHETER PRECISION INC / VTAK FAQ

What is the ChartMill fundamental rating of CATHETER PRECISION INC (VTAK) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VTAK.


What is the valuation status for VTAK stock?

ChartMill assigns a valuation rating of 1 / 10 to CATHETER PRECISION INC (VTAK). This can be considered as Overvalued.


Can you provide the profitability details for CATHETER PRECISION INC?

CATHETER PRECISION INC (VTAK) has a profitability rating of 1 / 10.


What is the financial health of CATHETER PRECISION INC (VTAK) stock?

The financial health rating of CATHETER PRECISION INC (VTAK) is 1 / 10.


Can you provide the expected EPS growth for VTAK stock?

The Earnings per Share (EPS) of CATHETER PRECISION INC (VTAK) is expected to grow by 96.27% in the next year.